PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS IN PATIENTS WHO ARE NAIVE TO TNF INHIBITORS

Trial Profile

PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS IN PATIENTS WHO ARE NAIVE TO TNF INHIBITORS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Etrolizumab (Primary) ; Adalimumab
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms HIBISCUS I
  • Sponsors Roche
  • Most Recent Events

    • 04 May 2016 Planned End Date changed from 1 Nov 2018 to 1 Mar 2018.
    • 04 May 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2018.
    • 31 Dec 2015 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018 as per ClinicalTrials.gov.record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top